

10/506743

DT09 Rec'd PCT/PTO 03 SEP 2004

"Express Mail" mailing label number EV 392094574 US

Date of Deposit

03 SEP 2004

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Printed Name

QUEEN THOMAS

Signature

Queen Thomas

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Joanne Sloane Lancaster
For : Antagonistic Anti-hFas Ligand
Human Antibodies and Fragments
Thereof
Docket No. : X-15450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

As a means of complying with the duty of disclosure, Applicants submit an "Information Disclosure Citation In An Application" on a Form PTO-1449 (modified) and provides a copy of each of the listed documents for consideration by the Examiner.

Since this Statement is being filed in accordance with 37 C.F.R. 1.97(b), Applicants submit that no additional fee is required.

Applicants request consideration of this information.

Respectfully submitted,

Thomas E. LaGrandeur

Thomas E. LaGrandeur
Agent for Applicant
Registration No. 51,026
Phone: 317-651-1527

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288

Sept. 1, 2004

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15450	Serial No 10/506743
	Applicants Joanne Sloan Lancaster	
	Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US 6,114,507	9/5/2004	Shirakawa, et al.	
	AB	US 6,348,334 B1	2/19/2002	Nagata, et al.	
	AC	US 6,096,312	8/1/2000	Nakamura, et al.	
	AD	US			
	AE	US			
	AF	US			
	AG	US			
	AH	US			
	AI	US			
	AJ	US			
	AK	US			
	AL	US			
	AM	US			
	AN	US			
	AO	US			
	AP	US			
	AQ	US			
	AR				

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15450	Serial No 10/506743
	Applicants Joanne Sloan Lancaster	
	Filing Date	Group

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ Kind Code ⁵ (if known)				
	BA	WO 95/18819	07/13/1995			
	BB					
	BC					
	BD					
	BE					
	BF					
	BG					
	BH					
	BI					
	BJ					
	BK					
	BL					
	BM					
	BN					
	BO					
	BP					
	BQ					
	BR					

FORM PTO 1449 (modified) INFORMATION DISCLOSURE CITATION IN AN APPLICATION	Atty. Docket No. X-15450	Serial No 10/506743
	Applicants Joanne Sloan Lancaster	
	Filing Date	Group

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
	CA	Tanaka, et al., "Expression of the functional soluble form of human FAS ligand in activated lymphocytes" <u>The EMBO J.</u> Vol. 14(6): 1129-1135 (1995)	
	CB	Suda, et al., "Expression of the Fas Ligand in Cells of T Cell Lineage" <u>J. Immunology</u> , Vol. 154: 3806-13 (1995)	
	CC	Hanabuchi, et al, "Fas and its ligand in a general mechanism of T-cell mediated cytotoxicity" <u>Proc., Natl. Acad. Sci. USA</u> , Vol. 91:4930-4 (1994)	
	CD	Kayagaki, et al., "Metalloproteinase-mediated Release of Human Fas Ligand", <u>J. Exp. Med.</u> , Vol. 182:1777-83 (1995)	
	CE	Elovaara, et al., "Upregulated expression of Fas ligand in brain through the spectrum of HIV-1 infection" <u>Acta Neuropathologica</u> , Vol. 98(4): 355-62 (1999)	
	CF	Nagata, et al., "The Fas Death Factor" <u>Science</u> Vol. 267: 1449-56 (1995)	
	CG	Arase, et al., "Fas-mediated Cytotoxicity by Freshly Isolated Natural Killer Cells" <u>J. Exp. Med.</u> Vol. 181:1235-8 (1995)	
	CH	Yagita, et al., "Fas-mediated Cytotoxicity - A New Immunoregulatory and Pathogenic Function of the Th1 CD4+ T Cells" <u>Immunol. Rev.</u> Vol. 146:223-39 (1995)	
	CI	Krammer, et al., "The Role of APO-1-Mediated Apoptosis in the Immune System" <u>Immunol. Rev.</u> Vol. 142:175-91 (1994)	
	CJ	Mariani, et al., "Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases" <u>Eur. J. Immunol.</u> Vol. 25:2303-2307 (1995)	
	CK	Nagata, "Fas Ligand-Induced Apoptosis" <u>Annu. Rev. Genet.</u> , Vol. 33: 29-55 (1999)	
	CL	Leroy, X, et al., "Immunohistochemical detection of Fas and Fas ligand in sarcomatoid renal cell carcinoma" <u>APMIS</u> , Vol. 109 :469-73 (2001)	
	CM	Miwa, et al., "Therapeutic effect of an anti-Fas ligand mAb on lethal graft-versus-host disease" <u>International Immunology</u> , Vol. 11(6): 925-931 (1999)	
	CN	Nakayama, et al., "Fas/Fas Ligand Interactions Play an Essential Role in the Initiation of Murine Autoimmune Diabetes" <u>Diabetes</u> , Vol. 51: 1391-97 (2002)	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.